Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC trimmed its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 49.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 8,318 shares of the company’s stock after selling 8,124 shares during the quarter. Headlands Technologies LLC’s holdings in Revolution Medicines were worth $364,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Revolution Medicines by 14.7% in the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company’s stock valued at $747,799,000 after purchasing an additional 2,185,082 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Revolution Medicines during the third quarter worth about $83,082,000. Norges Bank acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $76,197,000. Pictet Asset Management Holding SA lifted its stake in shares of Revolution Medicines by 4,399.6% during the fourth quarter. Pictet Asset Management Holding SA now owns 712,596 shares of the company’s stock valued at $31,169,000 after buying an additional 696,759 shares during the period. Finally, Geode Capital Management LLC boosted its position in Revolution Medicines by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 4,086,199 shares of the company’s stock worth $180,171,000 after acquiring an additional 459,174 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RVMD has been the topic of a number of recent analyst reports. HC Wainwright increased their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Wedbush reiterated an “outperform” rating and set a $67.00 target price on shares of Revolution Medicines in a research report on Thursday, February 27th. Needham & Company LLC lowered their price target on Revolution Medicines from $60.00 to $59.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Stifel Nicolaus cut their price objective on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, UBS Group boosted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Twelve equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $65.23.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $32.87 on Friday. The business’s 50-day moving average is $39.80 and its two-hundred day moving average is $45.33. The firm has a market capitalization of $6.11 billion, a PE ratio of -9.16 and a beta of 1.37. Revolution Medicines, Inc. has a 12 month low of $29.55 and a 12 month high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Equities analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Insider Activity

In related news, COO Margaret A. Horn sold 3,058 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares in the company, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 1,864 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares of the company’s stock, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by company insiders.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.